Journal Article Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT

Ishiyama, Ken  ,  Yamaguchi, Takuhiro  ,  Eto, Tetsuya  ,  Ohashi, Kazuteru  ,  Uchida, Naoyuki  ,  Kanamori, Heiwa  ,  Fukuda, Takahiro  ,  Miyamura, Koichi  ,  Inoue, Yoshiko  ,  Taguchi, Jun  ,  Mori, Takehiko  ,  Iwato, Koji  ,  Morishima, Yasuo  ,  Nagamura-Inoue, Tokiko  ,  Atsutao, Yoshiko  ,  Sakamaki, Hisashi  ,  Takami, Akiyoshi

47pp.47 - 53 , 2016-08-01 , Elsevier
Acute erythroid leukemia (FAB-M6) and acute megakaryoblastic leukemia (FAB-M7) exhibit closely related properties in cells regarding morphology and the gene expression profile. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the mainstay of the treatment for both subtypes of leukemia due to their refractoriness to chemotherapy and high rates of relapse, it remains unclear whether allo-HSCT is curative in such cases due to their scarcity. We retrospectively examined the impact of allo-HSCT in 382 patients with M6 and 108 patients with M7 using nationwide HSCT data and found the overall survival (OS) and relapse rates of the M6 patients to be significantly better than those of the M7 patients after adjusting for confounding factors and statistically comparable with those of the patients with M0/M1/M2/M4/M5 disease. Consequently, the factors of age, gender, performance status, karyotype, disease status at HSCT and development of graft-vs.-host disease predicted the OS for the M6 patients, while the performance status and disease status at HSCT were predictive of the OS for the M7 patients. These findings substantiate the importance of distinguishing between M6 and M7 in the HSCT setting and suggest that unknown mechanisms influence the HSCT outcomes of these closely related subtypes of leukemia. © 2016 Elsevier Ltd.
Embargo Period 12 months

Number of accesses :  

Other information